Vertex Pharmaceuticals (VRTX)

EBITDA Growth

19.92%

TTM · Period ending:

VRTX logo

VRTX EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported19.92%
VRTX TTM EBITDA YoY % (46.34% → 19.92%)
High-resolution chart · PNG

VRTX ebitda growth history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Vertex Pharmaceuticals EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-248.186%
32.1791%
30.0848%
76.6998%
65.2267%
3.6641%
-30.1981%
-113.6477%
-42.2027%
-80%
-106.4935%
-79.5918%
-81.3253%
6.7797%
42.1053%
36.3636%
29.3617%
8.1712%
-16.6667%
20.0692%
5.6225%
-29.798%
-32.5581%
-28,800%
-2,866.6667%
-460%
-437.2549%
98.5294%
113.4328%
166.2651%
171.831%
-11.4754%
-28.8462%
-84.4444%
-222.7273%
10.2941%
0%
-18.4211%
46.3415%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.